Yamada, Yuji
Takano, Harumasa http://orcid.org/0000-0001-8492-1533
Yamada, Maki
Satake, Naoko
Hirabayashi, Naotsugu
Okazaki, Mitsutoshi
Nakagome, Kazuyuki
Article History
Received: 4 July 2018
Accepted: 21 November 2018
First Online: 6 December 2018
Ethics approval and consent to participate
: Not applicable.
: We obtained written informed consent for publication of anonymized case details from the patient.
: HT has received grants from Biogen Japan, Eli Lilly Japan, Nippon Boehringer Ingelheim, Sumitomo Dainippon Pharma, Meiji Seika Pharma, Nihon Medi-Physics, Janssen Pharmaceutical, Tanabe Mitsubishi Pharma, Otsuka Pharmaceutical, and Mochida Pharmaceutical, and speaker’s honoraria from Biogen Japan. NS received research funding from Meiji Seika Pharma and Sumitomo Dainippon Pharma. MO received research funding from Eisai,Janssen Pharmaceutical,Meiji Seika Pharma,MSD,Novartis Pharma,Otsuka Pharmaceutical,Quintiles Pharma,UCB Japan,Sumitomo Dainippon Pharma. KN has received lecture fees from Kyowa Hakko Kirin, Otsuka Pharmaceutical, Sumitomo Dainippon Pharma, Eli Lilly Japan, Shionogi, Meiji Seika Pharma, Pfizer Japan, MSD, GlaxoSmithKline, Janssen Pharmaceutical, Mochida Pharmaceutical, and Yoshitomiyakuhin, and participated in an advisory board for Otsuka Pharmaceutical, Nippon Boehringer Ingelheim, Takeda Pharmaceutical, Toyama Chemical, Sumitomo Dainippon Pharma, Meiji Seika Pharma, Pfizer Japan, Janssen Pharmaceutical, and Mochida Pharmaceutical, and received research funding from Mitsubishi Tanabe Pharma, Asahi Kasei Pharma, Astellas Pharma, Mochida Pharmaceutical, Meiji Seika Pharma, Otsuka Pharmaceutical, Nippon Boehringer Ingelheim, and Sumitomo Dainippon Pharma.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.